Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Immunic, Inc. logo

Immunic, Inc. (IMUX) Stock Ticker

NASDAQ: IMUX · Healthcare · Biotechnology
$9.35+0.27%
USD · as of 2026-09-27 · market cap $127.3M
Open IMUX in TickrDownload for iPhone

IMUX right now

Down 33% in the last month.
Options expect by Oct 6±8.5%
Options expect by Oct 29±17.5%
Priced in for Nov 12 earnings±21.2%
IV rank (30-day)8% · cheap
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full IMUX picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on IMUX
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Immunic, Inc.

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.

IMUX stock facts

Ticker symbolIMUX
ExchangeNASDAQ Global Select
SectorHealthcare
IndustryBiotechnology
Market cap$127.3M
CEOErik Lundgren
Employees100
HeadquartersNew York City, NY, US
IPO date2014-04-17
Websiteimux.com

What you can see for IMUX on Tickr

Live IMUX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the IMUX report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Immunic, Inc.?

The ticker symbol for Immunic, Inc. is IMUX, listed on the NASDAQ Global Select.

What is IMUX?

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other…

HomeExploreMarketLists
All pages